Malaysia's IHH Healthcare Berhad has announced that its Singaporean subsidiary, Northern TK Venture Pte Ltd (NTK), has raised its damage claim against Japan's Daiichi Sankyo to JPY 199.8 billion ...

Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) from Japan's Daiichi Sankyo for its stake buy in India's Fortis Healthcare.

New Delhi, Feb 6 (PTI) Malaysia's IHH Healthcare Berhad on Thursday said its Singaporean arm Northern TK Venture Pte Ltd has increased the claim for damage from Japan's Daiichi Sankyo to up to JPY 199 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This study examines the interannual and seasonal variations in the distribution of radioactive materials released from the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident in the surface layer ...

Japanese drugmaker Daiichi Sankyo (TYO: 4568) has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025. Dr Manabe will transition from his current role ...

NEW YORK – AstraZeneca and Daiichi Sankyo have begun treating high-risk non-small cell lung cancer patients with their TROP2-directed antibody drug conjugate Datroway (datopotamab deruxtecan) and ...

As­traZeneca and Dai­ichi Sankyo’s an­ti­body-drug con­ju­gate En­her­tu is now ap­proved to treat a new sub­set of breast can­cer pa­tients with very low lev­els of HER2 … ...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...